Introduction and Objectives: Coagulase-negative staphylococci (CoNS) are relatively low in virulence but some are increasingly recognized as agents of clinically important infections. Glycopeptides are the drugs of choice for treatment of methicillin-resistant CoNS infections. Our aim was to analyse the susceptibility profile of CoNS in our healthcare network from 2010-2012.
Introduction
Coagulase-negative staphylococci (CoNS) comprise about 30 species of which around half are normal flora of humans. Staphylococcus epidermidis is commonly identified as an agent of clinically important infections due to CoNS.
The major risk factor for CoNS infections is the presence of implanted biomedical devices such as catheters, prosthetic joints, cardiac pacemakers and CSF shunts. 2 Some CoNS are able to colonise polymer surfaces by the formation of a thick, adherent, multilayered biofilm which can interfere with host defense mechanisms such as opsonophagocytosis. 3 Over the past few decades, the significance of CoNS has increased due to the growing number of device implantations and immunocompromised patients. CoNS are now the second most common cause of prosthetic valve endocarditis after S. aureus and one of the most frequent pathogens isolated from deep-seated prosthetic implant infections. 4, 5 CoNS have also become one of the most common causes of bacteraemia in immunosuppressed patients. 2 Treatment of CoNS infections can be challenging owing to the frequent presence of foreign materials and increasing antimicrobial resistance. Resistance to methicillin in CoNS is very common among isolates recovered from hospitalized individuals. 6 Glycopeptides are usually the drugs of choice for treatment of methicillin-resistant CoNS infections. However, CoNS have become increasingly resistant to glycopeptides such as teicoplanin. 7 Moreover, vancomycin resistant subpopulations have also been identified within the teicoplanin non-susceptible group of CoNS. 8 We reviewed the antibiotic susceptibilities of CoNS over a 3-year period, with the main emphasis being teicoplanin susceptibility versus non-susceptibility. This data regarding antibiotic resistance of CoNS may have an influence on the choice of empirical treatment regimens.
Materials and methods

Setting
This study was conducted at Monash Health; a large healthcare network with over 2000 acute and sub-acute inpatient beds located over five geographically distinct sites. Data was collected on all CoNS with susceptibilities performed by the microbiology laboratory from 1 st January 2010 to 31 st December 2012. The susceptibility testing was done only for clinically significant cases eg. clinician's request, presence of central line, and multiple positive blood cultures. Susceptibility testing was performed on urine if there was a raised WBC, a heavy pure growth, and/or catheter samples were obtained from symptomatic patients. Other non-urinary samples were tested for susceptibility if CoNS were present in pure growth or from a sterile site with a foreign body.
Annual reports for teicoplanin and vancomycin usage rates at Monash Health were extracted for 2010-2012 (personal communication) from the National Antimicrobial Utilisation Surveillance Program (NAUSP), for the two acute hospital sites (Monash Medical Centre (MMC) and Dandenong Hospital (DH) and their associated 14 and 26 bed intensive care units (ICUs). 9 Rates were expressed as defined daily doses (DDD) per 1,000 occupied bed days (OBDs).
Microbiology
Gram positive cocci were presumptively identified as CoNS by standard laboratory methods (Gram stain, colony morphology, catalase and coagulase tests). Isolates were further identified to species level using Vitek 2 GP card (BioMerieux Inc., Durham, NC) or BBL Crystal Gram positive identification system for species level identification (BD, Sparks, USA). If identification to species level fell below 85% confidence, staphylococcal isolates were simply referred to as CoNS. Urine CoNS isolates were screened with a novobiocin disc to identify S. saprophyticus and if sensitive, the isolates were not further identified.
Raw data was extracted directly from the Vitek 2 Advanced Expert System (AES, BioMerieux Inc., Durham, NC) and interpreted using the Clinical and Laboratory Standards Institute (CLSI) guidelines for all antistaphylococcal antibiotics (oxacillin, rifampicin, daptomycin and vancomycin) except for fusidic acid in which the Comité de l′ Antibiogramme de la Société Française de Microbiologie (CA-SFM) criteria was used. Two different Vitek susceptibility cards had been used during this period: P579 GPS card was used prior to 15 th October 2010 whereas P612 GPS card was used after this date and contained additional wells for the antibiotic daptomycin. Teicoplanin minimum inhibitory concentrations (MICs) were categorized into two groups; teicoplanin susceptible (Teico-S, teicoplanin MIC 4 or ≤ 8 µg/ml) and non-susceptible (Teico-NS, teicoplanin MIC ≥ 16 µg/ml).
Sample site
Clinical sample sites were categorised as sterile (blood, tissue, body fluids including cerebrospinal fluid (CSF) and peritoneal fluid), and non-sterile (urine and swabs obtained from superficial wounds or eyes). Patient location was collected from the patient information system and categorised as ICU or non-ICU.
Repeat samples originating from the same patients and site within 14 days were excluded.
Analysis
Baseline comparisons between the type of antibiotics, sample site and patient location were made using chi-square (χ 2 ) Fisher's exact analysis with Stata 12 (StataCorp, College Station, TX, USA).
Results
Sample site
Susceptibility testing was performed on 1510 CoNS, of which 715 Teico-S and 85 Teico-NS were from sterile site isolates and 686 Teico-S and 24 Teico-NS were from non-sterile sites.
Of the CoNS tested, 53% (800/1510) were from sterile sites with over half originating from blood (55.3%), followed by tissue (21.9%) and fluid (18.6%) respectively. Most isolates from non-sterile samples were from urine specimens (678/710, 95.5%).
Teicoplanin non-susceptibility was significantly higher from sterile site isolates (10.6%) compared to non-sterile site isolates (3.4%) (p<0.001).
Species identification
Of the 1510 isolates tested, 941 (62%) were identified to species level. Seventeen different species were identified, with S. epidermidis predominating (43.3%). There was a significantly greater number of S. epidermidis in the Teico-NS group compared to Teico-S group (p<0.001) ( Table 1) . antistaphylococcal antibiotics compared to the Teico-S group (p<0.001). Of the isolates from ICU, 13.7 % were found to be Teico-NS compared to 6.2 % of the non-ICU isolates (p<0.001).
There was no significant difference in teicoplanin resistance between the two geographically distinct ICUs (p=0.43).
Rising Teicoplanin MIC with prolonged exposure to vancomycin
There were five patients who had the same CoNS repeatedly but with rising MIC against teicoplanin (Table 3 ). All these patients were treated with vancomycin.
Vancomycin and Teicoplanin non-susceptible isolates
There were four patients with CoNS (all tissue specimens) which were not susceptible to teicoplanin, vancomycin or daptomycin. All had received antibiotic treatment with cefazolin or ceftriaxone prior to infection with CoNS, while only two had been treated with vancomycin (Table 4) Antimicrobial usage NAUSP specific data for glycopeptides showed an average of 30 DDD/1,000 OBDs at MMC and 34 DDD/1,000 OBDs at DH. These two hospitals provided over 70% of acute care at our healthcare network. 
Discussion
This study aimed to analyse the susceptibility profiles of CoNS, with emphasis on teicoplanin non-susceptibility and its relationship to vancomycin in our multi campus healthcare network.
There is limited available local information in the literature concerning CoNS and glycopeptide resistance. Ma et al reported on 745 isolates using microbroth dilution and found that there had been an increase in CoNS Teico-NS from 4.5% in 2008 to 6.7% in 2009, while all isolates remained susceptible to vancomycin. 8 Other studies have reported reduced susceptibility overall to glycopeptides at 5.1% and teicoplanin at 8.1%. 2 Similarly, our study showed 7.2% of isolates to be Teico-NS with vancomycin resistance at 0.3%.
Prolonged exposure to vancomycin is a possible risk factor for the development of resistance to teicoplanin. 10 It has been shown that stepwise exposure to vancomycin can induce resistance, particularly in S. haemolyticus and S. epidermidis. 7 This is possible since the gene for teicoplanin resistance is co-located with another antibiotic resistance gene/s.
The most frequent species detected in Teico-NS CoNS in our study was S. epidermidis (96.2% compared to 38.5% of Teico-S CoNS). Reduced susceptibility to glycopeptides has previously been most commonly seen in S. haemolyticus but this was quite rare (0.6%) in our study collection. 8, 11, 12 Other species which have been reported to be glycopeptide non-susceptible include S. lugdunensis, S. capitis and S. simulans. 2, 4, 6, 13 However, none of these species were identified as Teico-NS in the current study. CoNS from patients in ICU were more likely to be Teico-NS. This could possibly be due to long-term exposure to multiple antibiotics which has selected for resistant strains.
Studies using population analysis profile (PAP) testing have shown that vancomycin heteroresistant phenotypes have been identified within Teico-NS isolates from patients who have had prolonged glycopeptide therapy. 8, 14 Although the mechanism of action is not clearly known, increased cell wall thickness in these subpopulations is similar to that seen for S. aureus heteroresistance when challenged with vancomycin. 10 It is not known why resistance develops sooner for teicoplanin than vancomycin and one theory proposed that teicoplanin binds more avidly to CoNS. 13 The main limitation of our study is that it was based on review of retrospective data and the clinical significance of the studied CoNS isolates had not been determined. Over a third of all CoNS (predominantly urines) were not further identified to species level by standard biochemical methods. Identification using matrix-assisted laser desorption ionization-time of flight mass spectrometry has only recently become available at our hospital site. Confirmation of true teicoplanin MIC using Etest was not conducted on Teico-NS isolates and we have relied on the three concentrations (4ug/ml, 8ug/ml, 16ug/ml) tested by Vitek. Isolates were not available for PAP testing and hence we are unable to confirm if hetero-resistant populations may be present. Molecular strain typing was not undertaken and it is possible that the same clonal strains of CoNS may be circulating in high-level care wards such as ICU. Importantly, some of our results may be skewed with regard to CoNS from ICU as such isolates are more likely to be investigated rather than considered to be non-significant.
Further surveillance is required to examine the prevalence of glycopeptide non-susceptible CoNS at other institutions. The mechanism of action needs to be clearly determined by studying cell wall membrane proteins and antibiotic binding sites. The implications for treatment with vancomycin requires further investigation and for the time being clinicians should be aware that potentially vancomycin resistance may be selected from teicoplanin non-susceptible strains.
Conclusion
In conclusion, for serious CoNS infections, susceptibility testing should be performed including testing for glycopeptides. This will allow for more appropriate antibiotic treatment of these difficult to treat infections
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